With $300 million in funding and multimodal patient data collected from more than 800 hospitals over a decade, Owkin's patient data-trained AI agents enable comprehensive and clinically relevant insights that more accurately reflect human disease compared to companies focused primarily on laboratory research data. Partnerships with Anthropic and eight of the top 10 global pharma companies underscore Owkin's capabilities.
Cyborg Score Rationale
Owkin has raised $354M over 13 rounds from 22 investors, achieved unicorn status, and recently secured major partnerships including a multi-year K Pro collaboration with Sanofi (June 2026) and a three-year licensing deal with AstraZeneca (May 2026) to access Owkin's K Pro AI platform. The company operates with significant pharma validation and proprietary patient data advantages.
Top Insights
Launched K Pro as agentic AI Scientist in June 2026 at BIO International Convention and announced multi-year collaboration with Sanofi (June 2026) to build AI agents for drug development.
Announced agentic infrastructure for biology at JPM Healthcare Conference 2026 (January 12) with integration of Claude for Healthcare and Life Sciences by Anthropic.
Spun out Waiv (formerly Owkin Dx) in March 2026 with $33 million Series A funding to develop AI-powered precision testing platform.
AstraZeneca inked three-year licensing deal (May 2026) for K Pro platform to analyze scientific, clinical, and competitive data more quickly.
Named Competitors
Foundation Medicine — AI technologies analyzing patient samples for cancer therapy selection
Tempus — AI platform for clinical decision-making and drug research
Caris Life Sciences — AI-powered precision oncology diagnostics
Anthropic Claude for Healthcare — AI infrastructure partner for healthcare applications
Recent Developments
(June 2026) Multi-year K Pro collaboration with Sanofi to build AI agents for biopharmaceutical R&D
(June 2026) Deepening collaboration with NVIDIA on Biological Artificial Super Intelligence models
(May 2026) Three-year licensing agreement with AstraZeneca for K Pro autonomous AI Scientist platform
(January 2026) Launched agentic infrastructure for biology with Pathology Explorer agent via Anthropic partnership
(March 2026) Spun out Waiv (formerly Owkin Dx) with $33M Series A funding for AI-enabled diagnostics
Open the full interactive Owkin report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.